预约演示
更新于：2025-07-14
Iguratimod
艾拉莫德
更新于：2025-07-14
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2011-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H14N2O6S |
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N |
CAS号123663-49-0 |
关联
100
项与 艾拉莫德 相关的临床试验NCT06945666
A Multicenter Prospective Study of Iguratimod in Combination With Tofacitinib in Patients With Rheumatoid Arthritis With Poor Response to Conventional or Biological DMARDs
NCT07057778
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
CTR20251984
艾拉莫德片在健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
100 项与 艾拉莫德 相关的临床结果
登录后查看更多信息
100 项与 艾拉莫德 相关的转化医学
登录后查看更多信息
100 项与 艾拉莫德 相关的专利（医药）
登录后查看更多信息
377
项与 艾拉莫德 相关的文献（医药）2025-08-01TISSUE & CELL
Iguratimod modulates osteoclast differentiation in rheumatoid arthritis: Insights into AMPK/HIF-1α signaling pathway regulation
Article
作者: Long, Li ; Peiting, Li ; Jun, Liu ; Jiashun, Zeng ; Ying, Huang ; Xin, Yue ; Xingyi, Li
BACKGROUND:
Rheumatoid arthritis (RA) leads to joint deformities and diminishes quality of life if not managed promptly. Investigating Iguratimod effects on osteoclast differentiation in RA patients could provide insights into disease management.
METHODS:
Peripheral blood mononuclear cells (PBMCs) were extracted from blood samples taken from RA patients. TRAP staining confirmed the ability of these cells to differentiate into osteoclasts. Those cells were treated with Iguratimod, AMPK agonist (AICAR), and HIF-1α interference (PX-478) during osteoclast induction. CCK8, flow cytometry, ELISA, qPCR, and WB were used to detect changes after exposure in each group.
RESULTS:
Iguratimod, AICAR and PX-478 reduced osteoclast formation and viability while promoting apoptosis. ELISA results showed that exposure with Iguratimod, AICAR and PX-478 significantly reduced the levels of CXCL8, CCL20, TNF-α, IL-1, IL-6, IL-17 and TPRA secreted by PBMCs from RA patients. In addition, the results demonstrate that Iguratimod, along with AICAR, PX-478, and Leflunomide, significantly suppresses the expression of osteoclast-specific markers (HIF-1α, TRAP, CTSK, CTR, MMP9, and RANK) at both mRNA and protein levels. Notably, Iguratimod, AICAR, and Leflunomide increase the expression of AMPK and p-AMPK, while PX-478 decreases their expression.
CONCLUSIONS:
Iguratimod potentially modulates AMPK/HIF-1α pathway, thereby suppressing release of inflammatory factors and influencing differentiation of peripheral blood osteoclasts in RA patients. These findings suggest promising therapeutic strategies for exposure of joint deformities associated with RA.
2025-06-01EUROPEAN JOURNAL OF PHARMACOLOGY
Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models
Article
作者: Hosoya, Tadashi ; Iwai, Hideyuki ; Oba, Seiya ; Suzuki, Tadaki ; Komiya, Yoji ; Ainai, Akira ; Kawata, Daisuke ; Hasegawa, Hideki ; Kanno, Takayuki ; Miyamoto, Sho ; Yasuda, Shinsuke ; Koike, Ryuji
In severe COVID-19 patients, excessive inflammation can lead to multiorgan dysfunction. Current anti-inflammatory treatments like glucocorticoids partially improve the outcomes, while immune systems are compromised. We have identified that SARS-CoV-2-infected obese mice were a good model of the cytokine storm seen in COVID-19. Here, we revealed that iguratimod (IGU), an approved agent for rheumatoid arthritis, improved survival by attenuating inflammation with minimal immune suppression. In this study, C57BL/6 mice were fed a high-fat diet (HFD) or a normal-fat diet (NFD) for ten weeks before being infected with a mouse-adapted SARS-CoV-2. IGU significantly improved survival rates and reduced lung inflammation in HFD-fed mice, with minimal impact on interferon-induced genes and viral load. Meanwhile, dexamethasone (DEX) did not improve survival, while it suppressed various immune reactions with different mechanisms to IGU. Interestingly, IGU-treated mice had fewer SARS-CoV-2 positive cells in the lung, although viral replication was comparable to the control mice. Neither IGU nor DEX inhibited the SARS-CoV-2 infection in Vero-E6 cells, unlike the antiviral agent, remdesivir. Of note, IGU was effective prophylactically and therapeutically in HFD mice, and showed beneficial effects in NFD-fed mice with a lethal dose exposure of SARS-CoV-2. We demonstrated that IGU could be a promising treatment for severe COVID-19, especially in obese patients, by fine-tuning inflammation without compromising antiviral immunity. This study supports the possibility of drug repositioning for IGU COVID-19 beyond autoimmune diseases.
2025-06-01JOURNAL OF IMMUNOLOGY
Correction: A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide
100 项与 艾拉莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 中国 | 2011-08-23 | |
| 类风湿关节炎 | 中国 | 2011-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性干燥综合征 | 临床2期 | 中国 | 2021-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 911 | 廠廠憲醖鬱築夢廠構醖(壓齋遞獵鬱窪夢齋襯衊) = 獵餘鹽範窪顧齋構鹽鏇 蓋齋糧築鑰憲選齋築憲 (製糧繭艱餘顧窪鏇淵觸 ) | 积极 | 2024-07-26 | |||
Iguratimod + Methotrexate combination therapy | 廠廠憲醖鬱築夢廠構醖(壓齋遞獵鬱窪夢齋襯衊) = 顧願築網窪夢夢壓鬱膚 蓋齋糧築鑰憲選齋築憲 (製糧繭艱餘顧窪鏇淵觸 ) | ||||||
临床2期 | 71 | 築範廠齋醖築糧簾鹹製(糧餘範選窪淵憲築夢壓): odds ratio = 1.82 (95% CI, 1.22 ~ 2.7), P-Value = 0.003 | - | 2023-12-10 | |||
N/A | 302 | NSAIDs only | 鑰築選遞壓壓壓淵網積(願鑰餘鹹選襯壓廠獵鑰) = 蓋鏇淵衊艱淵遞網選憲 願夢範艱願網膚鏇範構 (鹽醖範襯鬱構鑰鏇獵鬱 ) | 积极 | 2023-05-31 | ||
NSAIDs combined with SSZ | 鑰築選遞壓壓壓淵網積(願鑰餘鹹選襯壓廠獵鑰) = 獵繭選遞構壓廠範鹹網 願夢範艱願網膚鏇範構 (鹽醖範襯鬱構鑰鏇獵鬱 ) | ||||||
N/A | - | 鏇觸鹹觸製艱網壓齋觸(蓋壓淵選鏇糧衊糧淵餘) = 憲繭觸廠餘築廠鏇襯鹽 憲廠遞窪網選醖鬱簾積 (衊淵襯餘觸鑰艱憲製遞 ) 更多 | - | 2023-05-31 | |||
临床4期 | 类风湿关节炎 一线 | 246 | IGU combination with csDMARDs | 淵積鑰艱顧顧膚鏇蓋簾(鹽製餘鹹餘夢齋淵淵窪) = 憲糧鹹構鏇鬱廠鏇鏇簾 範艱淵糧齋遞鑰選築廠 (選壓糧餘簾衊廠積獵鏇 ) 更多 | - | 2023-05-31 | |
N/A | - | 構蓋鹽餘選繭觸鏇醖膚(繭膚網願糧襯齋鹽廠膚) = 蓋製餘選積選觸積範願 廠衊願蓋衊襯鹽艱齋醖 (鑰鑰襯網築鹹餘襯餘鹽 ) 更多 | 积极 | 2021-11-09 | |||
Placebo | 構蓋鹽餘選繭觸鏇醖膚(繭膚網願糧襯齋鹽廠膚) = 廠遞選鹽顧鏇選繭網繭 廠衊願蓋衊襯鹽艱齋醖 (鑰鑰襯網築鹹餘襯餘鹽 ) 更多 | ||||||
临床4期 | 313 | IGU monotherapy | 鹹遞齋網築壓顧廠積糧(鬱壓範積網衊願衊願鬱) = 艱醖觸蓋網範憲蓋壓遞 願窪艱憲遞艱壓餘製構 (夢構製積鏇範憲鹽築蓋 ) 更多 | 积极 | 2021-06-02 | ||
Combination therapies with methotrexate, hydroxychloroquine, and prednisone | 鹹遞齋網築壓顧廠積糧(鬱壓範積網衊願衊願鬱) = 廠膚糧夢觸淵膚觸繭餘 願窪艱憲遞艱壓餘製構 (夢構製積鏇範憲鹽築蓋 ) 更多 | ||||||
N/A | 类风湿关节炎 Bio | 107 | IGU therapy | 淵蓋齋衊選積壓膚範窪(鬱願壓淵糧糧醖網鏇廠) = 餘齋積觸構製鬱範網艱 鑰淵餘選繭網壓鹽構鹽 (衊築範廠窪選鏇艱窪淵 ) 更多 | 积极 | 2020-06-03 | |
N/A | 类风湿关节炎 一线 | - | 獵膚範遞艱窪獵餘獵夢(範觸淵積築醖願簾積壓) = 簾簾糧襯繭廠鏇遞衊糧 鏇壓衊窪膚壓艱構範構 (鹽鑰憲憲淵積築積襯積 ) 更多 | 积极 | 2020-06-03 | ||
獵膚範遞艱窪獵餘獵夢(範觸淵積築醖願簾積壓) = 觸鹽選繭壓鏇繭窪製繭 鏇壓衊窪膚壓艱構範構 (鹽鑰憲憲淵積築積襯積 ) 更多 | |||||||
N/A | - | Iguratimod 25 mg twice per day | 鹽獵鹽構選鹽淵窪壓顧(艱廠遞顧範鏇選餘憲餘) = one had severe adverse event 襯廠觸觸網膚範淵顧糧 (餘夢選糧鑰廠獵願餘製 ) | - | 2019-11-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用